The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trialsKey Takeaways:Participants receiving the highest dose in the 48-week Chinese trial were said to lose up to 19.2% of their weightThe Hengrui Pharma drug targets the same receptors as Eli Lilly's blockbuster product tirzepatide A leading Chinese drug developer has moved a step closer to joining multinationals in the booming market for weight-lo ...